The money will help the Franklin Lakes, N.J.-based company boost its production capacity by 50 percent and produce more than 12 million test kits per month by next February, it said.
“Making COVID-19 diagnostic tests widely available is critical to expanding rapid detection of COVID-19 infections and mitigating the impact of the disease by identifying affected patients, quickly quarantining infectious individuals and tracing their contacts,” said Dave Hickey, Beckton, Dickinson & Co.’s president of integrated diagnostic solutions. “This investment will bolster our U.S. manufacturing capabilities, helping us quickly scale our production of point-of-care COVID-19 tests to ensure we have a robust supply for our U.S. customers.”
Read the full news release here.
More articles on supply chain:
FDA puts hand sanitizers on import alert, adds more to do-not-use list
Freight, shipping companies say they’re not ready to distribute COVID-19 vaccine
See-through masks in high demand as COVID-19 cases rise
